Nathaniel R Smilowitz1, Pritha Subramanyam2, Eugenia Gianos1, Harmony R Reynolds1, Binita Shah1,3, Steven P Sedlis1,3. 1. Department of Medicine, Division of Cardiology, NYU School of Medicine. 2. Department of Medicine, Icahn School of Medicine at Mount Sinai. 3. Department of Medicine, Section of Cardiology, Veterans Affairs New York Harbor Healthcare System, New York Campus, New York City, New York, USA.
Abstract
BACKGROUND: Type 2 myocardial infarction (MI) is defined by a rise and fall of cardiac biomarkers and evidence of ischemia without unstable coronary artery disease (CAD) because of a mismatch in myocardial oxygen supply and demand. Myocardial injury is similar but does not fulfill the clinical criteria for MI. There is uncertainty in terms of the clinical characteristics, management, and outcomes of type 2 MI and myocardial injury in comparison with type 1 MI. PATIENTS AND METHODS: Patients admitted to a Veterans Affairs tertiary care hospital with a rise and fall in cardiac troponin were identified. MI and injury subtypes, presentation, management, and outcomes were determined. RESULTS: Type 1 MI, type 2 MI, and myocardial injury occurred in 137, 146, and 175 patients, respectively. Patients with type 2 MI were older (P=0.02), had lower peak cardiac troponin (P<0.001), and were less likely to receive aspirin and statin at discharge (P<0.001) than type 1 MI survivors. All-cause mortality (median follow-up: 1.8 years) was not different between patient groups (type 1 MI mortality: 29.9%, type 2 MI: 30.8%, myocardial injury: 29.7%; log rank P=0.94). A significant proportion of deaths were attributed to cardiovascular causes in all subgroups (type 1 MI: 34.1%, type 2 MI: 17.8%, myocardial injury: 30.8%). CONCLUSION: Patients with type 2 MI and myocardial injury were less likely to receive medical therapy for CAD than those with type 1 MI. No differences in all-cause mortality among MI subtypes were observed. Additional studies to determine optimal medical therapy and risk stratification strategies for these high-risk populations are warranted.
BACKGROUND:Type 2 myocardial infarction (MI) is defined by a rise and fall of cardiac biomarkers and evidence of ischemia without unstable coronary artery disease (CAD) because of a mismatch in myocardial oxygen supply and demand. Myocardial injury is similar but does not fulfill the clinical criteria for MI. There is uncertainty in terms of the clinical characteristics, management, and outcomes of type 2 MI and myocardial injury in comparison with type 1 MI. PATIENTS AND METHODS: Patients admitted to a Veterans Affairs tertiary care hospital with a rise and fall in cardiac troponin were identified. MI and injury subtypes, presentation, management, and outcomes were determined. RESULTS: Type 1 MI, type 2 MI, and myocardial injury occurred in 137, 146, and 175 patients, respectively. Patients with type 2 MI were older (P=0.02), had lower peak cardiac troponin (P<0.001), and were less likely to receive aspirin and statin at discharge (P<0.001) than type 1 MI survivors. All-cause mortality (median follow-up: 1.8 years) was not different between patient groups (type 1 MI mortality: 29.9%, type 2 MI: 30.8%, myocardial injury: 29.7%; log rank P=0.94). A significant proportion of deaths were attributed to cardiovascular causes in all subgroups (type 1 MI: 34.1%, type 2 MI: 17.8%, myocardial injury: 30.8%). CONCLUSION:Patients with type 2 MI and myocardial injury were less likely to receive medical therapy for CAD than those with type 1 MI. No differences in all-cause mortality among MI subtypes were observed. Additional studies to determine optimal medical therapy and risk stratification strategies for these high-risk populations are warranted.
Authors: Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Kristian Thygesen; Joseph S Alpert; Harvey D White; Allan S Jaffe; Hugo A Katus; Fred S Apple; Bertil Lindahl; David A Morrow; Bernard R Chaitman; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Jeroen J Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasche; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; Jose-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis; Jeroen J Bax; Helmut Baumgartner; Claudio Ceconi; Veronica Dean; Christi Deaton; Robert Fagard; Christian Funck-Brentano; David Hasdai; Arno Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Theresa McDonagh; Cyril Moulin; Bogdan A Popescu; Zeljko Reiner; Udo Sechtem; Per Anton Sirnes; Michal Tendera; Adam Torbicki; Alec Vahanian; Stephan Windecker; Joao Morais; Carlos Aguiar; Wael Almahmeed; David O Arnar; Fabio Barili; Kenneth D Bloch; Ann F Bolger; Hans Erik Botker; Biykem Bozkurt; Raffaele Bugiardini; Christopher Cannon; James de Lemos; Franz R Eberli; Edgardo Escobar; Mark Hlatky; Stefan James; Karl B Kern; David J Moliterno; Christian Mueller; Aleksandar N Neskovic; Burkert Mathias Pieske; Steven P Schulman; Robert F Storey; Kathryn A Taubert; Pascal Vranckx; Daniel R Wagner Journal: J Am Coll Cardiol Date: 2012-09-05 Impact factor: 24.094
Authors: Lotte Saaby; Tina Svenstrup Poulsen; Axel Cosmus Pyndt Diederichsen; Susanne Hosbond; Torben Bjerregaard Larsen; Henrik Schmidt; Oke Gerke; Jesper Hallas; Kristian Thygesen; Hans Mickley Journal: Am J Med Date: 2014-01-21 Impact factor: 4.965
Authors: Aisha Etaher; Derek Chew; Julie Redfern; Tom Briffa; Chris Ellis; Christopher Hammett; Jeffrey Lefkovits; John Elliott; Louise Cullen; David Brieger; John K French Journal: Heart Lung Circ Date: 2016-12-31 Impact factor: 2.975
Authors: Tomasz Baron; Kristina Hambraeus; Johan Sundström; David Erlinge; Tomas Jernberg; Bertil Lindahl Journal: Heart Date: 2014-10-20 Impact factor: 5.994
Authors: Nathaniel R Smilowitz; Matthew C Weiss; Rina Mauricio; Asha M Mahajan; Kaitlyn E Dugan; Arvind Devanabanda; Claudia Pulgarin; Eugenia Gianos; Binita Shah; Steven P Sedlis; Martha Radford; Harmony R Reynolds Journal: Int J Cardiol Date: 2016-05-13 Impact factor: 4.164
Authors: Kris G Vargas; Paul M Haller; Bernhard Jäger; Maximilian Tscharre; Ronald K Binder; Christian Mueller; Bertil Lindahl; Kurt Huber Journal: Clin Res Cardiol Date: 2018-12-07 Impact factor: 5.460
Authors: Xiongyi Han; Myung Ho Jeong; Liyan Bai; Joon Ho Ahn; Dae Young Hyun; Kyung Hoon Cho; Min Chul Kim; Doo Sun Sim; Young Joon Hong; Ju Han Kim; Youngkeun Ahn Journal: Cardiovasc Diagn Ther Date: 2022-02
Authors: Hanumantha R Jogu; Sameer Arora; Muthiah Vaduganathan; Arman Qamar; Ambarish Pandey; Parag A Chevli; Tusharkumar H Pansuriya; Muhammad I Ahmad; Abhishek Dutta; Padageshwar R Sunkara; Waqas Qureshi; Sujethra Vasu; Bharathi Upadhya; Deepak L Bhatt; James L Januzzi; David Herrington Journal: Clin Cardiol Date: 2019-04-12 Impact factor: 2.882
Authors: Andrew R Chapman; Philip D Adamson; Anoop S V Shah; Atul Anand; Fiona E Strachan; Amy V Ferry; Kuan Ken Lee; Colin Berry; Iain Findlay; Anne Cruikshank; Alan Reid; Alasdair Gray; Paul O Collinson; Fred Apple; David A McAllister; Donogh Maguire; Keith A A Fox; Catalina A Vallejos; Catriona Keerie; Christopher J Weir; David E Newby; Nicholas L Mills Journal: Circulation Date: 2019-10-07 Impact factor: 29.690
Authors: Christopher Reid; Ahmed Alturki; Andrew Yan; Derek So; Dennis Ko; Jean-Francois Tanguay; Amal Bessissow; Shamir Mehta; Shaun Goodman; Thao Huynh Journal: CJC Open Date: 2020-02-24
Authors: John Hung; Andreas Roos; Erik Kadesjö; David A McAllister; Dorien M Kimenai; Anoop S V Shah; Atul Anand; Fiona E Strachan; Keith A A Fox; Nicholas L Mills; Andrew R Chapman; Martin J Holzmann Journal: Eur Heart J Date: 2021-07-08 Impact factor: 35.855